{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:35Z","timestamp":1794273875445,"version":"4.9.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jbc.2026.113680","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:20:44Z","timestamp":1792682444000},"page":"113680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BET Family Proteins Directly Regulate Constitutive TDO2 Transcription in Cancer Cells"],"prefix":"10.1016","author":[{"given":"Takafumi","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-9920","authenticated-orcid":false,"given":"Akira","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113680_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1042\/BST0370408","article-title":"Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase","volume":"37","author":"Rafice","year":"2009","journal-title":"Biochem. Soc. Trans"},{"key":"10.1016\/j.jbc.2026.113680_bib2","first-page":"13","article-title":"The kynurenine pathway presents multi-faceted metabolic vulnerabilities in cancer","author":"Le\u00f3n-Letelier","year":"2023","journal-title":"Front. Oncol"},{"key":"10.1016\/j.jbc.2026.113680_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues","volume":"3","author":"Th\u00e9ate","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jbc.2026.113680_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.gene.2007.04.010","article-title":"Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice","volume":"396","author":"Ball","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.jbc.2026.113680_bib5","article-title":"Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113680_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","article-title":"Targeting the IDO1\/TDO2-KYN-AhR Pathway for Cancer Immunotherapy","volume":"39","author":"Cheong","year":"2018","journal-title":"Challenges and Opportunities Trends Pharmacol. Sci"},{"key":"10.1016\/j.jbc.2026.113680_bib7","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.7150\/jca.31727","article-title":"Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications","volume":"10","author":"Ye","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.jbc.2026.113680_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fimmu.2015.00034","article-title":"Tryptophan-degrading enzymes in tumoral immune resistance","volume":"6","author":"van Baren","year":"2015","journal-title":"Front. Immunol"},{"key":"10.1016\/j.jbc.2026.113680_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.113680_bib10","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol"},{"key":"10.1016\/j.jbc.2026.113680_bib11","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbc.2026.113680_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond Semin","volume":"41","author":"Muller","year":"2019","journal-title":"Immunopathol"},{"key":"10.1016\/j.jbc.2026.113680_bib13","first-page":"2134","article-title":"Phase 1\/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies Clin","volume":"31","author":"Luke","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jbc.2026.113680_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/11786469221138456","article-title":"Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase","volume":"15","author":"Yoshioka","year":"2022","journal-title":"Int J Tryptophan Res"},{"key":"10.1016\/j.jbc.2026.113680_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbc.2026.113680_bib16","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev"},{"key":"10.1016\/j.jbc.2026.113680_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2026.113680_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115037","article-title":"PROTACS: A technology with a gold rush-like atmosphere","volume":"247","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem"},{"key":"10.1016\/j.jbc.2026.113680_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31913-5","article-title":"Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase","volume":"8","author":"Shibata","year":"2018","journal-title":"Sci. Rep"},{"key":"10.1016\/j.jbc.2026.113680_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41419-019-1793-9","article-title":"Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l-kynurenine","volume":"10","author":"Tian","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jbc.2026.113680_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fimmu.2020.00657","article-title":"Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C\/EBPbeta","volume":"11","author":"Kudo","year":"2020","journal-title":"Front. Immunol"},{"key":"10.1016\/j.jbc.2026.113680_bib22","doi-asserted-by":"crossref","unstructured":"Lee, R., Li, J., Li, J., Wu, C. J., Jiang, S., Hsu, W. H. et al. (2022) Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer Cancer Discov. 12, 1702\u20131717","DOI":"10.1158\/2159-8290.CD-21-0680"},{"key":"10.1016\/j.jbc.2026.113680_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107479","article-title":"Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors","volume":"208","author":"Bechter","year":"2020","journal-title":"Pharmacol. Ther"},{"key":"10.1016\/j.jbc.2026.113680_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106833","article-title":"Targeting the epigenetic reader \"BET\" as a therapeutic strategy for cancer","volume":"140","author":"Wahi","year":"2023","journal-title":"Bioorg. Chem"},{"key":"10.1016\/j.jbc.2026.113680_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011102","article-title":"BET Proteins as Attractive Targets for Cancer Therapeutics","volume":"22","author":"Sarnik","year":"2021","journal-title":"Int. J. Mol. Sci"},{"key":"10.1016\/j.jbc.2026.113680_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2019.08.013","article-title":"BET protein targeting suppresses the PD-1\/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response","volume":"465","author":"Andrieu","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jbc.2026.113680_bib27","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jbc.2026.113680_bib28","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1016\/j.ymthe.2022.07.022","article-title":"BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther"},{"key":"10.1016\/j.jbc.2026.113680_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1632446","article-title":"IDO and TDO inhibitors in cancer immunotherapy: mechanisms, clinical development, and future directions","volume":"16","author":"Al-Zoubi","year":"2025","journal-title":"Front. Pharmacol"},{"key":"10.1016\/j.jbc.2026.113680_bib30","article-title":"Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cells","volume":"14","author":"Kang","year":"2024","journal-title":"Front. Oncol"},{"key":"10.1016\/j.jbc.2026.113680_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000870","article-title":"Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jbc.2026.113680_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/pro.70152","article-title":"Phosphorylation of ITIM motifs drives the structural transition of indoleamine 2,3-dioxygenase 1 between enzymatic and non-enzymatic states","volume":"34","author":"Hoffka","year":"2025","journal-title":"Protein Sci"},{"key":"10.1016\/j.jbc.2026.113680_bib33","article-title":"Moonlighting Proteins Are Important Players in Cancer Immunology Front","volume":"11","author":"Adamo","year":"2020","journal-title":"Immunol"},{"key":"10.1016\/j.jbc.2026.113680_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680896","article-title":"Adverse pro-tumorigenic effects of IDO1 catalytic inhibitors mediated by the non-enzymatic function of IDO1 in tumor cells","volume":"16","author":"Rossini","year":"2025","journal-title":"Front. Immunol"},{"key":"10.1016\/j.jbc.2026.113680_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s42004-025-01648-2","article-title":"Ligand-induced conformations and dynamic allosteric motions of IDO1 affecting the recruitment of a protein signaling partner","volume":"8","author":"Coletti","year":"2025","journal-title":"Commun Chem"},{"key":"10.1016\/j.jbc.2026.113680_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1134551","article-title":"The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1","volume":"14","author":"Panfili","year":"2023","journal-title":"Front. Immunol"},{"key":"10.1016\/j.jbc.2026.113680_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"10.1016\/j.jbc.2026.113680_bib38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-023-01715-3","article-title":"The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling","volume":"25","author":"Sharma","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jbc.2026.113680_bib39","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.jbc.2026.113680_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175265","article-title":"Induced protein degradation for therapeutics: past, present, and future","volume":"134","author":"Yoon","year":"2024","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.jbc.2026.113680_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.gde.2024.102181","article-title":"Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors","volume":"86","author":"Gold","year":"2024","journal-title":"Curr. Opin. Genet. Dev"},{"key":"10.1016\/j.jbc.2026.113680_bib42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41594-024-01384-6","article-title":"Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity","volume":"32","author":"Zhang","year":"2025","journal-title":"Nat. Struct. Mol. Biol"},{"key":"10.1016\/j.jbc.2026.113680_bib43","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425812122","article-title":"Discovery of an LSD1 PROTAC degrader","volume":"122","author":"Hosseini","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.jbc.2026.113680_bib44","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.jbc.2026.113680_bib45","doi-asserted-by":"crossref","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","article-title":"Discovery of KT-474\u2500a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases J","volume":"67","author":"Zheng","year":"2024","journal-title":"Med. Chem"},{"key":"10.1016\/j.jbc.2026.113680_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41594-020-0394-8","article-title":"Roles of the BRD4 short isoform in phase separation and active gene transcription","volume":"27","author":"Han","year":"2020","journal-title":"Nat. Struct. Mol. Biol"},{"key":"10.1016\/j.jbc.2026.113680_bib47","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1126\/science.aaz4427","article-title":"Partitioning of cancer therapeutics in nuclear condensates","volume":"368","author":"Klein","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jbc.2026.113680_bib48","doi-asserted-by":"crossref","unstructured":"Sabari, B. R., Dall'Agnese, A., Boija, A., Klein, I. A., Coffey, E. L., Shrinivas, K. et al. (2018) Coactivator condensation at super-enhancers links phase separation and gene control Science 361,","DOI":"10.1126\/science.aar3958"},{"key":"10.1016\/j.jbc.2026.113680_bib49","first-page":"15","article-title":"Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers Trends Pharmacol","volume":"47","author":"Zhang","year":"2026","journal-title":"Sci"},{"key":"10.1016\/j.jbc.2026.113680_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41421-023-00544-0","article-title":"BRD4-targeting PROTAC as a unique tool to study biomolecular condensates","volume":"9","author":"Shi","year":"2023","journal-title":"Cell Discov"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826025524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826025524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:09:54Z","timestamp":1794272994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826025524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S0021925826025524"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113680","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BET Family Proteins Directly Regulate Constitutive TDO2 Transcription in Cancer Cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113680"}}